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primary treatment goals were reductions of the risk of bone complications and 
associated bone pain.
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Objectives: Clinical guidelines now are commonly used in many settings, though 
the impact of these guidelines on real world practice remains less clear. The 
USPSTF recently dropped recommendations for breast cancer screening among 
women aged 75+ years. Prior studies using survey data suggest that the guideline 
revision had no effect on screening behavior. Using registry and claims data, we 
assessed changes in screening patterns, and stage at diagnosis, among female 
Medicare beneficiaries aged 75+years compared with 65-74 years. MethOds: 
We examined 2003-11 biennial mammography screening rates using national 
Medicare fee-for-service claims (20% random sample), and linked SEER registry-
Medicare claims databases. Using linear regression models with a patient-level 
fixed effect, we estimated the change in proportion of subjects receiving screening 
over time (as well as the rate of incident cases of earlier vs. later stage cancer), 
among subjects aged 75+yo compared with younger subjects, i.e., a difference-in-
difference design. Results: We find a decrease in screening rate among women 
aged 75+ years after the revision (2011 vs. 2003-2008, and the difference in changes 
compared with younger women was 13.2% (95%CI:13.1-13.3%). Similarly, we find 
a relative decrease in the population rate of incident cases of earlier-stage cancer 
(0.12%, 95%CI: 0.07-0.17), increases in later-stage cancer. cOnclusiOns: With the 
guideline revision, there were relative decreases in screening rates among women 
aged 75+ years, compared with younger women. There also was a breast cancer 
stage shift, with more later-stage cancers and fewer earlier-stage cancers detected. 
Future evaluations on survival are needed. Moreover, as health insurance plans 
increasing link benefit designs with guidelines, the likelihood that guidelines will 
impact practice patterns could grow.
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Objectives: To compare the treatment patterns and resulting quality adjusted 
life year (QALY) in patients of Head & Neck cancers under private payment scheme 
(PPS) and government scheme (GS). MethOds: In a prospective study treatment 
orders of patients on chemotherapy for head & neck cancers were reviewed and 
patients were interviewed for six treatment cycles to assess treatment patterns in 
an oncology hospital having dedicated wards for patients under GS. Direct medi-
cal cost, indirect medical cost and non-medical costs associated with treatment 
were calculated for patients under PPS and GS and were compared. EQ-5D-5L 
instrument was administered to assess patient utility with treatment during 
each cycle. Results: A total of 104 patients (n= 49 under PPS, n= 55 under GS) 
were enrolled in the study after obtaining their informed consent. Majority of the 
patients under PPS were on Paclitaxel based regimen (63%) followed by primary 
protocol ((Docetaxel+ Cyclophosphamide+ Fluorouracil, (8%)). Most of the patients 
under GS were treated with Cisplatin with radiation therapy (82%) and none of the 
eligible patients under GS had privilege of treatment with primary protocol due 
to limited budget. Treatment compliance to NCCN guidelines for patients under 
PPS and GS was 89% and 58% respectively. Common adverse events like vomiting, 
constipation, neutropenia, fatigue and myalgia were higher in patients under GS 
than PPS. Average cost of treatment for PPS and GS per cycle was US $125 and US $30 
respectively. QALY gained by patients under PPS and GS after six cycles was 0.024 
and 0.014 respectively and the difference was found to be statistically significant 
(p< 0.05). cOnclusiOns: Treatment patterns in patients under PPS were well com-
pliant to NCCN guidelines. Limited budget of government scheme in a developing 
country does not allow clinicians to prescribe required anti-cancer medicines and 
supportive care. Patients under GS can be benefited with more utility with additional 
increment in the budget.
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Objectives: This signal detection pharmacovigilance activity aims to determine 
if treatment with desloratadine is associated with more than expected report-
ing of torsade de pointes and electrocardiogram QT prolongation (TQP) events 
in real-world settings. MethOds: Adverse event reports submitted to the FDA 
Adverse Event Reporting System were used (cumulative to June 2014), and Multi-
item Gamma Poisson Shrinker disproportionality analysis algorithm was applied 
to calculate Empirical Bayes Geometric Mean (EBGM) and corresponding 95%CI as 
association metrics. Desloratadine was defined by generic name, and ventricular 
tachycardia events were defined as structured MedDRA queries of Preferred Terms 
denoting to TQP. Reporting profile was compared to loratadine, the parent drug of 
desloratadine. Arrhythmogenic antihistamines, astemizole and terfenadine, were 
used as positive controls. Results: Seventeen reports of TQP were submitted 
for desloratadine corresponding to 59% male users (mean age 44 years), and 17% 
and 35% of TQP events were life-threatening and lead to patient hospitalization, 
demographics, comorbidities, therapy type, treatment initiator, and concomitant 
medications were descriptively examined across the EU-5 and by individual coun-
try. Results: A total of 64,932 patients from Germany (24,577), France (12,574), 
Italy (11,676), UK (8,427), and Spain (7,698) were included. The majority were male 
(64%, except Germany was 50%), > 56 years (70%), and had chemo-radiation (91%). 
Comorbidities were similar across countries, except COPD (5%, whereas Spain was 
19%) and Cardiac Dysfunction (4%, whereas Germany was 21%). Except in the UK, 
temozolomide was used, on average, for 82% of front-line patients with treatment 
being initiated by a radiologist (58%) or medical oncologist (23%). In the UK, temo-
zolomide was used for 65% of front-line patients and was initiated by a radiologist 
90% of the time. Surgical procedures including Excision of Lesion, Craniotomy, and 
Lobectomy were performed, on average, in 67% of patients, except in France (44%). 
However, French patients were more likely to have a Burr Hole Biopsy (43%) versus 
the other 4 countries (average of 20%). Frequently used concomitant medications 
were corticosteroids (3-fold variation across EU-5), anti-emetics (5-fold variation), 
and gastrointestinal medications (on average 20%). cOnclusiOns: The common 
front-line treatment for glioblastoma was found to be surgery followed by temozolo-
mide chemotherapy, consistent with guidelines. However, there was some variation 
across countries with regards to the type of surgery, comorbidities, chemotherapy 
initiator, and concomitant medications. Further study is needed to comprehensively 
characterize glioblastoma treatment patterns in the EU-5.
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Objectives: To examine bone pain and BTA treatment patterns in patients with 
BMs from BC in real-world setting in Europe. MethOds: The study was conducted 
using the Adelphi Breast Cancer Disease-Specific Programme (DSP) 2015 database, a 
multi-country cross-sectional survey of 385 oncologists from 6 European countries 
(UK, Germany, France, Italy, Spain, and Belgium). Each physician completed a patient 
record form (PRF) for 10 patients being treated for advanced BC that captured the 
following information: presence of BMs, current pain state, current analgesic use, 
BTA treatment, and reasons behind BTA treatment decisions. Results: A total 
of 1376 patients with BM from BC were identified. At the time of survey (an aver-
age of 11 months after diagnosis of BMs), 47% of the patients experienced mild 
pain; and 20% had moderate/severe pain. The majority of the patients (96%) with 
pain took analgesic drugs to manage pain, which included 28% (n= 260) patients 
treated with strong opioids (e.g. morphine, oxycodone etc.). Of them, 59% (154/260) 
still experienced moderate/severe bone pain. Among the patients with BMs, 88% 
(n= 1210) were treated with a BTA. Of them, 81% (n= 979) received treatment within 
3 months of BMs diagnosis. Reasons for BTA treatment initiation within 3 months 
of BMs were “bone pain” (34%), “high risk of bone complications” (31%), “number of 
BMs” (13%), “location of BMs” (8%) and “prior history of bone complications” (7%). 
Reasons for not treating patients with BTAs were “recent diagnosis” (40%), “low bone 
complication risk” (17%), “focus on treating primary tumor” (10%), and “short life 
expectancy” (10%). cOnclusiOns: Bone pain is the main symptom encountered 
by patients with BMs from BC. Most of these patients treated with strong opioids 
still experienced moderate/severe bone pain. The majority of patients with BMs 
received BTAs; primary treatment goals were reductions of bone pain and risk of 
bone complications.
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Objectives: To examine bone pain and BTA utilization in patients with BMs from 
PC in real-world setting in Europe. MethOds: This study was conducted using 
the Adelphi Prostate Cancer Disease Specific Programme (DSP) 2015 database, a 
multi-country cross-sectional survey of 241 oncologists and 103 urologists in 6 
European countries (UK, Germany, France, Italy, Spain, and Belgium). Patients’ 
current pain state, current analgesic use, BTA treatment, and reasons for BTA 
treatment data were extracted from the patient record forms (PRFs) completed 
by the physicians. Results: A total of 3608 PRFs were collected including 1931 on 
PC patients with BMs. At the time of survey (an average of 15.2 months from BMs 
diagnosis), 41% patients experienced mild pain; and 29% had moderate/severe 
bone pain. The majority of the patients (96%) with pain took analgesics to manage 
pain, including 29% (n= 387) patients who were treated with strong opioids (e.g. 
morphine, oxycodone etc.). Of these patients, 73% (284/387) still had moderate/
severe pain. Among the patients with BMs, 74% (n= 1437) were treated with a BTA, 
and BTA treatment occurred within 3 months of BMs diagnosis in 72% (n= 1036) 
of them. Reasons for BTA treatment initiation within 3 months of BMs were “bone 
pain” (40%), “high risk of bone complications” (29%), “number of BMs” (11%), “loca-
tion of BMs” (8%) and “prior history of bone complications” (5%). Reasons for not 
treating patients with BTA were “recent diagnosis” (36%), “low bone complication 
risk” (22%), and “focus on treating primary tumor” (8%). cOnclusiOns: Bone pain 
is the major symptom encountered by patients with BMs from PC. The majority 
of these patients treated with strong opioids still experienced moderate/severe 
bone pain. Approximately three quarters of patients with BMs received BTAs; 
